ENGAIN: Advancements in Varicose Vein Treatment Devices

Engain is making headway with its new varicose vein treatment device called Venocclo. This device aims for a significant market presence, with expected clinical approval in June 2025 and a planned release in July.

What is Venocclo?

Venocclo utilizes a third-generation technique to treat varicose veins by sealing them with a special adhesive, setting it apart from traditional surgical and laser methods.

• Compares favorably with Medtronic’s VenaSeal
• Uses N-butyl cyanoacrylate for treating veins
• Offers advantages in safety, pricing, and ease of use

Key Features of Venocclo

Engain highlights several competitive edges:

1. Safety: In trials, Venocclo had no reports of phlebitis-like reactions, which are common with competing products.
2. Ease of use: Improved procedural efficiency via a unique device setup reduces treatment time and potential complications.
3. Cost efficiency: Aims to release at a more competitive price compared to high-cost alternatives like VenaSeal.

Additional Product Development

Engain is conducting clinical trials for Kipza, a treatment for musculoskeletal pain:

• Blocks abnormal micro-vessels causing inflammation and pain.
• Kipza’s embolic agents dissolve within 24 hours, minimizing risk of complications.
• Ongoing trials compare Kipza with conventional treatments in knee osteoarthritis patients.

Company Growth and Expansion Plans

Engain plans an IPO by the end of 2025 or early 2026 to fund further development and commercialization of its medical devices.

• Aims for leadership in the market for varicose vein and musculoskeletal pain treatments.
• Increased revenues expected with potential sales expansion in international markets.
• Continues to leverage its polymer chemistry expertise for innovative medical solutions.

Final Thoughts

Engain’s commitment to pioneering safer and more effective medical devices highlights its potential in the competitive healthcare market. With Venocclo nearing launch and Kipza on its way, Engain is poised for significant growth and impact in medical technology.

Table of Contents

1. Introduction
   • Overview of Engain and Its Market Focus
2. Venoclo: Next-Gen Varicose Vein Treatment
   • Technology and Mechanism
   • Comparison with Medtronic’s VenaSeal
   • Core Benefits: Safety, Pricing, Usability
3. Venoclo’s Market Readiness
   • Clinical Approval Timeline
   • Projected Launch Date
   • Strategic Positioning
4. Kipza: Treating Musculoskeletal Pain
   • Mechanism of Action and Dissolving Embolic Agent
   • Clinical Trials and Use Case in Knee Osteoarthritis
5. Engain’s Business Strategy & Growth Plans
   • IPO Preparation and Capital Strategy
   • Global Market Expansion Goals
   • Strength in Polymer Chemistry Innovation
6. Conclusion
   • Engain’s Role in Future Medical Solutions
   • Anticipated Impact of Venoclo and Kipza